Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

ZINZINO AB (PUBL.): New study unveils global snapshot on Omega-3 deficiency - and why high-precision testing plus an enhanced formula can close the gap


News provided by

Zinzino

18 Aug, 2025, 14:20 GMT

Share this article

Share toX

Share this article

Share toX

GOTHENBURG, Sweden, Aug. 18, 2025 /PRNewswire/ -- A groundbreaking study published in Lipids in Health and Disease (9 August 2025) reveals that the vast majority of individuals worldwide have insufficient omega-3 levels, despite widespread supplement use, highlighting a critical global health need. The analysis, covering more than 590,000 whole-blood dried blood spot samples, was conducted using Zinzino's proprietary BalanceTest database – the world's largest of its kind to date.

Key insights from the study: 

  • Widespread omega-3 deficiency: Across diverse regions, participants—including those reporting use of omega-3 supplements – frequently failed to reach optimal levels, with consistently elevated omega-6:3 ratios. Zinzino's omega-3 supplement BalanceOil+ was not part of the evaluation.

  • Regional disparities: Coastal diets rich in seafood showed relatively higher omega-3 status, while inland regions with typical Western diets lagged behind.

  • Testing is essential: These results validate the necessity of measuring rather than guessing – objective blood testing like the BalanceTest is crucial to evaluate nutritional status accurately and guide effective interventions.

A powerful combination: Test-based nutrition + advanced delivery

"This study is a milestone for us," says Dr. Colin Robertson, Chief Product Officer at Zinzino. "For the first time, we have published data in a peer-reviewed scientific journal – Lipids in Health and Disease – which has been a collaboration between our in-house research team, our Scientific Advisory Board, and the independent analytical contract lab Vitas AS. This is not just a publication; it's hard evidence that we are shaping global nutrition science with real-world evidence from a global population."

"The world has moved beyond one-size-fits-all solutions. This study underscores that many supplements in the market fall short – and targeted, scientifically designed formulations paired with accurate, large-scale measurement are critical to closing the nutritional gap.

"The BalanceTest provides a scientifically validated, standardized, and scalable method to assess omega-3 status and omega-6:3 balance – all from a simple dried blood spot sample. It delivers precise, reproducible results that allow both individuals and health professionals to track nutritional status and guide targeted, evidence-based interventions," Dr. Robertson concludes.

Why this matters now
While the study establishes an essential baseline for global omega3 status, the next frontier lies in improving supplementation. That's where Zinzino's BalanceOil comes in—a carefully crafted, proprietary blend (60% high-quality fish oil rich in EPA and DHA, 40% extra virgin olive oil), fortified with polyphenols, natural tocopherols, and vitamin D. This design enhances oxidative stability and bioavailability, aiming to support better omega-3 blood levels and balanced fatty acid ratios.

With omega-3 levels tied to cognitive function, cardiovascular health, and inflammation control, the implications of this study are both clinical and strategic. Some populations eat fish regularly, others hardly at all. And while supplementation is promoted, the actual omega-3 status of individuals – and entire populations – has been largely unknown due to lack of objective measurement. Testing offers a roadmap: start with a scientific measurement (BalanceTest), follow up with a superior formulation (BalanceOil), and continue supplementing and testing to close the nutritional gap. Public health guidelines recommend higher intakes of omega-3, but diets vary enormously by culture and country. 

"Our results provide the most comprehensive picture to date of omega-6:3 balance worldwide," says Dr. Martina Torrissen, Research & Development Specialist at Zinzino and co-author of the article.

"By identifying critical gaps, this research helps guide public health priorities and empowers companies like Zinzino to deliver personalized solutions that address real needs in global nutrition," Dr. Torrissen concludes.

The motto 'Test, don't guess' is central to Zinzino's test-based nutrition philosophy and represents a leap forward in personalized health and wellness.

"For Zinzino, this is more than science – it validates our mission," says CEO Dag Pettersen. "By combining personalized, test-based nutrition with one of the world's largest fatty acid databases, we are not only transforming individual lives but also shaping the future of preventive health on a global scale."

"One of our greatest strengths is that the BalanceTest can literally measure the world," says Pettersen. "Unlike surveys or population samples based on blood plasma, which require complex lab work, we have developed a reliable, highly sensitive tool that measures people's health status — right from their own homes."

About BalanceTest

The BalanceTest is an at-home dried blood spot (DBS) test that delivers reliable readings of omega-3 status and fatty acid balance. Administered via a fingertip sample, it's processed by Vitas, an independent, GMP-certified lab in Oslo, Norway, delivering scientific clarity on health markers like Omega-3 index, cell membrane fluidity, and mental resilience. 

About BalanceOil 

BalanceOil+ is a purpose-built omega-3 supplement featuring a 60:40 fish oil plus extra virgin olive oil ratio, supplemented with vitamin D and natural tocopherols for enhanced stability and absorption, designed to help users achieve and sustain a balance of omega-6 and omega-3 blood levels linked with health benefits.

About Zinzino

Zinzino is a global direct sales company from Scandinavia specializing in test-based, personalized nutrition and scientific skincare. It is a public limited company with its shares listed on Nasdaq First North Premier Growth Market. Their scientifically proven nutritional supplements are available in more than 100 markets across the world. The company headquarters is in Gothenburg, Sweden with additional offices in Europe, Asia, and Australia.

Publication details

  • Title: Global variations in omega-3 fatty acid status and omega-6:omega-3 ratios: insights from >500,000 wholeblood dried blood spot samples

  • Journal: Lipids in Health and Disease (2025), Article Number: 260

For more information:
Dag Pettersen CEO Zinzino +47 (0) 932 25 700, dag@zinzino.com

Pictures for publication free of charge:
marketing@zinzino.com

Certified Adviser:
DNB Carnegie Investment Bank AB (publ.)

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/zinzino/r/zinzino-ab--publ--new-study-unveils-global-snapshot-on-omega-3-deficiency---and-why-high-precision-t,c4219442

The following files are available for download:

https://mb.cision.com/Public/10976/4219442/9dc66554db497988.pdf

Zinzino-unveils-global-snapshot-on-omega-3-deficiency-en-202508

https://news.cision.com/zinzino/i/balancetest,c3461316

BalanceTest

Modal title

Also from this source

ZINZINO AB (PUBL): Share subscription due to warrants

In the option programme Zinzino's general meeting decided on 2020-05-15, 87,650 B shares have been subscribed. The price per share was SEK 45 and in...

ZINZINO AB (PUBL.): PRELIMINARY SALES REPORT JULY 2025

The revenue in July for Zinzino's sales markets increased by 64% and amounted to SEK 259.9 (158.8) million. Faun Pharma's external sales decreased...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

Supplementary Medicine

Supplementary Medicine

Household, Consumer & Cosmetics

Household, Consumer & Cosmetics

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.